Baseline Characteristics of 274 GEP NET Patients
| Patients (n) | ||
| Characteristic | Yes | No |
| Male | 139 (51) | 135 (49) |
| Age ≥ 70 y | 52 (19) | 222 (81) |
| Karnofsky performance status ≤ 70 | 38 (14) | 236 (86) |
| Elevated chromogranin A level | 72 (26) | 202 (74) |
| Bone metastases | 59 (22) | 215 (78) |
| Patients who met inclusion criteria | 252 (92) | 22 (8) |
| Previous therapy | ||
| Chemotherapy | 26 (10) | 248 (90) |
| Radiotherapy (external) | 18 (7) | 256 (93) |
| NET location | ||
| Gastrointestinal | 172 (63) | |
| Pancreas | 86 (31) | |
| Bronchus | 16 (6) | |
| Tumor uptake on baseline [111In-DTPA0]octreotide scan | ||
| Less than normal liver | 8 (3) | |
| Equal to or higher than normal liver | 203 (74) | |
| Higher than kidneys | 63 (23) | |
| Tumor mass on baseline [111In-DTPA0]octreotide scan | ||
| Limited and moderate | 223 (81) | |
| Extensive | 51 (19) | |
| Cumulative administered activity* | ||
| ≤22.2 GBq | 73 (27) | |
| 22.3–29.6 GBq | 122 (44) | |
| 29.7–44.4 GBq | 71 (26) | |
| 44.5–59.2 GBq | 8 (3) | |
| Age range at first treatment | ||
| 15–29 y | 1 (0.5) | |
| 30–44 y | 31 (11.5) | |
| 45–59 y | 109 (40) | |
| 60–74 y | 110 (40) | |
| 75–89 y | 23 (8) | |
↵* 177Lu-DOTATATE.
Data in parentheses are percentages.